This study investigated the safety of intravenous ketamine treatment for treatment-resistant depression (TRD) in patients with major depressive disorder (MDD) and bipolar depression (BP), focusing on the interplay between comorbidities, dissociation, and psychomimetic symptoms. 49 inpatients received ketamine infusions. Epilepsy was significantly associated with increased Brief Psychiatric Rating Scale (BPRS) scores over time. Other comorbidities showed insignificant effects on psychotic symptomatology. Post-dose CADSS and BPRS scores decreased after each infusion, except in the epilepsy subgroup. The study highlights the importance of considering comorbidities and concomitant medication when administering ketamine, emphasizing the need for close clinical supervision.
Publisher
Pharmaceuticals
Published On
Jan 24, 2023
Authors
Adam Włodarczyk, Alicja Dywel, Wiesław Jerzy Cubała
Tags
ketamine
treatment-resistant depression
comorbidities
major depressive disorder
bipolar depression
epilepsy
psychomimetic symptoms
Related Publications
Explore these studies to deepen your understanding of the subject.
